Κατά την διάρκεια των εργασιών του Παγκόσμιου Συνεδρίου έγινε από το Πανεπιστήμιο της Πενσυλβάνια στην Φιλαδέλφεια των ΗΠΑ (UPenn) η ακόλουθη σημαντική ανακοίνωση:

In partnership with IBA Proton Therapy, we are excited to announce that the U.S. Food and Drug Administration (FDA) has approved IBA’s Investigational Device Exemption. This approval will enable the first human feasibility clinical study in the United States for ConformalFLASH® proton therapy. The Pilot Study (C-FLASH-01) is expected to launch in summer 2026, led by Principal Investigator Alexander Lin, MD.

Dr. Lin, presented on the clinical study design last week at Annual Conference of the Particle Therapy Cooperative Group (PTCOG). This is a prospective study that will enroll 10 patients who require re-irradiation in the head and neck region, with the goal of assessing the clinical feasibility of ultra-high-dose-rate conformal proton therapy and to monitor potential acute toxicity.

James M. Metz, MD, says: “This milestone marks an important step in advancing proton flash therapy toward clinical evaluation. Together, we aim to establish the medical framework needed to study this promising approach and better understand how it may benefit patients in the future.”

Read more about the FDA approval here: https://lnkd.in/eCAM8Z-i